AASLD 2026

AASLD 2026
November 05-09, 2026
Denver, CO

American Association for the Study of Liver Diseases, The Liver Meeting®.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (14)

    Clinically Significant Portal Hypertension May Improve in Some Patients With Chronic Hepatitis Delta After 48 Weeks of Bulevirtide Treatment: A Pooled Analysis of Phase 2/3 Clinical Trials

    • Author(s): Reiberger, T
    • hepcludex
    • Liver Diseases

    Combining PAGE-B Score with FibroTest Improves Hepatocellular Carcinoma Risk Stratification in Patients Treated With Tenofovir-Based Treatment

    • Author(s): Sonneveld, M
    • vemlidy
    • Liver Diseases

    On-Treatment and Posttreatment Patterns of NonInvasive Tests of Fibrosis With Long-Term Bulevirtide Treatment for Chronic Hepatitis Delta: An Integrated Analysis

    • Author(s): Asselah, T
    • hepcludex
    • Liver Diseases

    Characteristics and Outcomes of On-Treatment ALT Flares in Patients with Hepatitis Delta Virus Receiving Bulevirtide and Pegylated Interferon Alfa

    • Author(s): Zoulim, F
    • hepcludex
    • Liver Diseases

    Integrated Efficacy Analysis of Bulevirtide 10 mg Monotherapy in Patients With Chronic Hepatitis Delta

    • Author(s): Lampertico, P
    • hepcludex
    • Liver Diseases

    Diagnostic Performance of Noninvasive Tests for Hepatic Fibrosis in Patients With Chronic Hepatitis Delta Receiving Bulevirtide

    • Author(s): Brunetto, M
    • hepcludex
    • Liver Diseases

    Seladelpar Is Associated With Stable Renal Function Over 5 Years of Treatment: Interim Results From the ASSURE Study

    • Author(s): Kowdley, K
    • livdelzi
    • Liver Diseases

    Seladelpar Downregulates Inflammatory and Fibrotic Pathways: Insights From Serum Proteomic Analysis

    • Author(s): Trauner, M
    • livdelzi
    • Liver Diseases

    Sustained Biochemical Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis, Including Those at High Risk for Progression, up to 5 Years of Treatment from ASSURE

    • Author(s): Kowdley, K
    • livdelzi
    • Liver Diseases

    Clinically Meaningful Fatigue Improvement With Seladelpar in Patients With Primary Biliary Cholangitis: Data From the Open-Label ASSURE Study

    • Author(s): Bonder, A
    • livdelzi
    • Liver Diseases

    Seladelpar Leads to Long-Term Efficacy and Safety in Patients with Prior OCA and/or Fibrate Exposure

    • Author(s): Kremer, A
    • livdelzi
    • Liver Diseases

    Seladelpar Leads to Durable and Significant Decrease in the Pruritogenic Cytokine IL-31, Associated With Pruritus Improvement: Long-Term Data From the ASSURE Study

    • Author(s): Mayo, M
    • livdelzi
    • Liver Diseases

    Seladelpar for Alkaline Phosphatase Normalization in Primary Biliary Cholangitis: Results from the IDEAL Phase III Randomized-Controlled Trial

    • Author(s): Levy, C
    • livdelzi
    • Liver Diseases

    Seladelpar Leads to Rapid and Sustained Alkaline Phosphatase Reduction, Regardless of Baseline Levels, Over 5 Years of Treatment in Patients with Primary Biliary Cholangitis

    • Author(s): Bowlus, C
    • livdelzi
    • Liver Diseases